Report Contents
Market Overview
The global Endobronchial Ultrasound (EBUS) Biopsy market is emerging as a critical segment within interventional pulmonology, with revenue expected to reach approximately USD 1.17 Billion in 2026 and expand toward USD 1.84 Billion by 2032, reflecting a projected compound annual growth rate of 7.60% over this period. This expansion is driven by rising lung cancer incidence, earlier adoption of minimally invasive diagnostics, and greater integration of EBUS into multidisciplinary thoracic oncology pathways across mature and emerging healthcare systems.
Strategic success in the EBUS Biopsy landscape hinges on scalable manufacturing, rigorous localization of solutions to meet varied reimbursement and procedural standards, and rapid technological integration of advanced imaging, navigation software, and AI-enabled decision support. Converging trends such as precision oncology, outpatient bronchoscopy suites, and value-based care are broadening procedural indications, shifting care settings, and redefining competitive dynamics. This report is positioned as an essential strategic tool for investors, device manufacturers, and providers, offering forward-looking analysis of critical capital allocation choices, market entry opportunities, and disruptive innovations that will shape the industry’s next growth cycle.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Endobronchial Ultrasound Biopsy Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Endobronchial Ultrasound Biopsy Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Convex probe endobronchial ultrasound bronchoscopes:
Convex probe endobronchial ultrasound bronchoscopes currently occupy the largest installed base within the endobronchial ultrasound biopsy market, as they are the primary platform for real-time mediastinal and hilar lymph node staging in lung cancer. Their integrated linear ultrasound transducer enables direct needle visualization during transbronchial needle aspiration, which underpins their central role in standard-of-care diagnostic algorithms in tertiary care hospitals and high-volume cancer centers. As lung cancer accounts for a significant portion of global oncology imaging and biopsy procedures, convex probe systems capture a correspondingly large share of procedure volume and recurring service revenue.
The competitive advantage of convex probe EBUS bronchoscopes lies in their ability to combine high-resolution ultrasound with bronchoscopy in a single pass, typically reducing diagnostic procedural time by an estimated 20.00–30.00% versus sequential CT-guided or surgical staging approaches. Their real-time needle tracking can improve diagnostic yield to rates often exceeding 85.00% for mediastinal lymph node sampling, which directly decreases the need for invasive mediastinoscopy and associated hospitalization costs by a meaningful margin. Ongoing growth is fueled by guideline-driven adoption of minimally invasive staging and an expanding base of interventional pulmonologists trained on convex probe platforms, especially in emerging markets where hospitals are upgrading from conventional bronchoscopy to image-guided systems.
Future expansion for convex probe EBUS bronchoscopes is catalyzed by the integration of advanced features such as elastography, enhanced Doppler modes and AI-assisted image interpretation that can improve tissue characterization and workflow efficiency. These innovations are estimated to increase per-room throughput by 10.00–15.00% through faster decision-making and fewer non-diagnostic passes, strengthening the economic case for capital investment. As global endobronchial ultrasound biopsy market revenues rise from ReportMines’ estimated USD 1.09 Billion in 2025 to USD 1.84 Billion by 2032 at a 7.60% CAGR, convex probe systems are positioned to retain a dominant share of equipment spending due to replacement cycles, software upgrades and integration with hospital-wide imaging ecosystems.
-
Radial probe endobronchial ultrasound systems:
Radial probe endobronchial ultrasound systems hold a strong and growing position in the diagnosis of peripheral pulmonary lesions, complementing convex probe systems that primarily target central airways and mediastinal structures. These devices use a rotating transducer at the tip of a thin, flexible catheter to generate 360-degree ultrasound images, enabling pulmonologists to locate small nodules that are invisible under conventional bronchoscopy. As low-dose CT screening programs identify an increasing volume of sub-centimeter and peripherally located nodules, radial probe systems are capturing a rising share of diagnostic workflows in comprehensive lung nodule clinics.
The core competitive advantage of radial EBUS lies in its ability to improve localization accuracy for peripheral lesions, which can increase diagnostic yield by approximately 15.00–25.00% compared with blind transbronchial biopsy in challenging anatomies. When radial EBUS is combined with navigation bronchoscopy or fluoroscopy, the probability of reaching lesions in the outer third of the lung is significantly higher, which can reduce repeat procedures and downstream imaging costs. This performance profile directly supports hospital return-on-investment models, as each successful radial EBUS-guided biopsy avoids the higher cost of surgical wedge resection or CT-guided transthoracic biopsy in a proportion of cases.
Radial probe endobronchial ultrasound systems are experiencing accelerated growth driven by the expansion of lung cancer screening programs and the migration of diagnostic care from surgery to interventional pulmonology suites. Technological shifts toward smaller probe diameters, improved image resolution and integration with electromagnetic navigation platforms are expected to raise procedure volumes per system by an estimated 10.00–20.00% over the medium term. As the global market expands at a 7.60% CAGR, radial EBUS systems are strategically positioned as a high-growth subsegment, particularly in regions where healthcare systems prioritize early-stage detection and minimally invasive diagnosis of peripheral lung disease.
-
Endobronchial ultrasound-guided biopsy needles:
Endobronchial ultrasound-guided biopsy needles represent a critical consumable segment in the global EBUS biopsy market, generating recurring revenue tied directly to procedure volumes rather than capital equipment cycles. These sterile, single-use needles are designed to pass through the working channel of convex and, in some setups, radial EBUS bronchoscopes to obtain cytology and tissue samples from lymph nodes and pulmonary lesions. Their importance is particularly pronounced in high-volume cancer centers, where the number of EBUS procedures per year can reach several hundred to several thousand, creating consistent demand regardless of economic cycles.
The competitive advantage of advanced EBUS biopsy needles stems from their optimized tip geometry, improved flexibility and enhanced echogenic markers, which together can increase tissue acquisition success rates and sample adequacy by an estimated 10.00–20.00% versus older-generation designs. Needles specifically engineered for core tissue sampling rather than cytology alone can reduce the rate of repeat biopsies and improve molecular profiling success, directly supporting targeted therapy and immunotherapy selection. This performance translates into clinically meaningful gains, such as higher rates of actionable genomic findings, while also lowering total cost of care by reducing additional diagnostic procedures.
Growth in the EBUS-guided biopsy needle segment is primarily driven by rising adoption of precision oncology protocols that require more extensive tissue samples for next-generation sequencing, PD-L1 testing and other biomarker panels. Each incremental biomarker assay increases the value of obtaining a high-quality specimen in a single procedure, which incentivizes hospitals and ambulatory centers to standardize on premium needle designs even at higher unit prices. As the overall endobronchial ultrasound biopsy market moves from USD 1.09 Billion in 2025 toward USD 1.84 Billion by 2032, the needle subsegment is expected to grow at or above the market CAGR, supported by a compounding effect of higher procedure counts and more complex diagnostic requirements per patient.
-
Endobronchial ultrasound processors and ultrasound consoles:
Endobronchial ultrasound processors and ultrasound consoles form the technological backbone of the EBUS ecosystem, providing the imaging, signal processing and user interface capabilities that define diagnostic performance. These capital systems are installed in bronchoscopy suites, hybrid operating rooms and interventional pulmonology laboratories, and they determine the quality of B-mode imaging, Doppler visualization and advanced modalities such as elastography. Their market position is central because every EBUS bronchoscope and probe must be paired with a compatible processor, making them a key determinant of system standardization across hospital networks.
The competitive advantage of modern EBUS consoles arises from superior image resolution, faster frame rates and advanced software algorithms that enhance contrast and reduce artifacts, collectively improving lesion delineation and needle visualization. High-end processors can reduce image interpretation time and adjustment of settings enough to shorten overall procedure duration by an estimated 10.00–15.00%, allowing more cases per room per day. In addition, networked consoles that integrate with PACS, electronic health records and hospital analytics platforms help facilities track diagnostic yield and utilization, enabling data-driven optimization that can improve resource use efficiency by a measurable margin.
Growth for endobronchial ultrasound processors and consoles is largely catalyzed by replacement of legacy imaging platforms, expansion of dedicated interventional pulmonology programs and regulatory approvals for new software features. Technological shifts toward AI-assisted image analysis, automated measurement tools and remote software upgrades are expected to extend console lifecycles while encouraging periodic software licensing revenues. As ReportMines forecasts the broader market to grow at a 7.60% CAGR through 2032, the console segment benefits from both new installations in emerging economies and upgrade cycles in mature markets, where hospitals seek to standardize on multi-modality platforms that support both EBUS and other ultrasound-guided interventions.
-
Endobronchial ultrasound accessories and single-use disposables:
Endobronchial ultrasound accessories and single-use disposables encompass a wide range of items such as guide sheaths, needle guides, valves, sterile caps, flushing systems and protective covers that are required for each EBUS procedure. This segment plays a pivotal role in ensuring procedural safety, infection control and equipment longevity, making it indispensable in daily operations across hospitals and ambulatory surgical centers. Because these products are used in every case, they generate a steady recurring revenue stream that is less sensitive to capital budgeting cycles and more closely correlated with procedure volume trends.
The competitive advantage of high-quality EBUS accessories and disposables is reflected in their ability to reduce cross-contamination risk, minimize device malfunction and streamline workflow. For example, the use of well-designed sterile valve sets and protective sheaths can reduce scope-related contamination events by a significant portion compared with reprocessed components, which directly impacts hospital infection metrics and regulatory compliance. Furthermore, guide sheaths that maintain stable positioning in peripheral airways can increase successful sampling of small lesions, contributing to higher diagnostic yield and reducing average fluoroscopy time by a measurable percentage, which in turn lowers radiation exposure and operational costs.
Growth in the accessories and single-use disposables segment is driven by stricter infection prevention standards, the global shift toward single-use components and the expansion of procedure volumes in both developed and emerging markets. As reimbursement schemes increasingly recognize the value of infection control and minimally invasive diagnostics, healthcare providers are more willing to standardize on premium disposable kits that package multiple accessories for efficiency. Given the projected rise of the global endobronchial ultrasound biopsy market from USD 1.09 Billion in 2025 to USD 1.84 Billion by 2032, the accessories and disposables category is well positioned to capture a growing share of incremental spending, supported by its high attachment rate to every EBUS-guided biopsy procedure and its alignment with hospital quality and safety priorities.
Market By Region
The global Endobronchial Ultrasound Biopsy market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a strategically critical hub for the Endobronchial Ultrasound Biopsy market, driven by high lung cancer incidence, advanced interventional pulmonology centers, and strong reimbursement structures. The United States and Canada jointly account for a significant portion of global revenue, supported by early adoption of EBUS-guided transbronchial needle aspiration and widespread use in staging and diagnosis. The region is characterized by a mature, high-value installed base that anchors the global market.
Future growth in North America will depend on expanding procedural volumes beyond tertiary hospitals into community pulmonology networks and integrated delivery systems. Untapped potential exists in remote and rural areas where access to EBUS remains limited, constrained by capital costs, lack of trained bronchoscopists, and uneven reimbursement for advanced bronchoscopy. Addressing these capability gaps through mobile EBUS programs, tele-mentoring, and vendor-backed training academies could unlock incremental demand and sustain mid‑single‑digit growth.
-
Europe:
Europe holds a substantial share of the Endobronchial Ultrasound Biopsy market, supported by robust national cancer screening initiatives and strong public healthcare funding. Germany, the United Kingdom, France, Italy, and Spain act as core demand centers, with high penetration of EBUS systems in university hospitals and specialist thoracic centers. The regional market profile is relatively mature, providing a stable revenue base that contributes meaningfully to global system and disposable probe sales.
However, considerable upside remains in Eastern and Southern Europe, where EBUS-guided biopsy is less consistently available in secondary hospitals. Market expansion is constrained by procurement budget cycles, heterogeneous reimbursement policies, and skills shortages in interventional pulmonology. Vendors that offer cost-effective platforms, shared-service models, and structured training pathways for bronchoscopy teams are well positioned to capture new installations and increase procedure adoption in underserved national health systems.
-
Asia-Pacific:
The broader Asia-Pacific region, excluding Japan, Korea, China, and the USA, is emerging as one of the fastest-growing zones for Endobronchial Ultrasound Biopsy, supported by rising lung cancer prevalence and rapid hospital infrastructure upgrades. Countries such as India, Australia, Singapore, and Indonesia are becoming important growth engines, with leading private hospital chains and tertiary government centers investing in EBUS platforms for minimally invasive mediastinal staging. The region is shifting from nascent adoption toward a high-growth phase.
Despite this momentum, a significant portion of the lung cancer patient population in Asia-Pacific still lacks access to EBUS-guided biopsy, particularly in secondary cities and rural provinces. Key obstacles include capital affordability, limited access to consumables, and shortage of trained bronchoscopists and anesthesiology support. Strategic opportunities lie in lower-cost system configurations, leasing and pay-per-use models, and targeted training partnerships with large hospital networks to accelerate diffusion beyond flagship metropolitan centers.
-
Japan:
Japan occupies a distinctive position in the Endobronchial Ultrasound Biopsy market due to its advanced healthcare infrastructure and high adoption of minimally invasive thoracic diagnostics. The country contributes a considerable share of Asia’s EBUS procedures, with university hospitals and large regional centers routinely using EBUS-TBNA in guideline-based lung cancer staging algorithms. The market is relatively mature, with high equipment penetration and a steady, procedure-driven revenue stream for probes and needles.
Incremental growth in Japan will stem from optimizing utilization across mid-sized community hospitals and increasing use of EBUS in combined diagnostic pathways with navigational bronchoscopy and robotic platforms. Challenges include an aging pulmonology workforce, strict capital budgeting, and pressure to demonstrate clear cost-effectiveness within the national health insurance framework. Opportunities exist for manufacturers that offer workflow-integrated imaging, extended probe life, and evidence-backed clinical outcomes to support reimbursement and protocol inclusion.
-
Korea:
Korea represents a technologically advanced and rapidly evolving Endobronchial Ultrasound Biopsy market within Asia, driven by high hospital digitalization and strong emphasis on early cancer detection. Large tertiary hospitals in Seoul and other metropolitan areas function as regional reference centers and account for most EBUS procedure volumes. The country’s contribution to global growth is notable, with a profile closer to high-growth rather than fully mature markets.
Untapped potential lies in extending EBUS access to smaller regional hospitals and broadening utilization beyond top academic centers. Barriers include concentration of expertise in a limited number of institutions, budget constraints in provincial facilities, and the need for standardized training curricula for respiratory physicians. Targeted initiatives such as manufacturer-supported simulation labs, shared-use systems across hospital alliances, and local clinical data generation can help accelerate adoption and solidify Korea’s role as an innovation test-bed in the region.
-
China:
China is one of the most dynamic and strategically important markets for Endobronchial Ultrasound Biopsy, underpinned by a very high lung cancer burden and aggressive expansion of tertiary hospitals. Leading cities such as Beijing, Shanghai, Guangzhou, and Shenzhen host major cancer centers that are rapidly increasing EBUS procedure volumes, making China a key driver of global growth. The market is transitioning from early adoption to scale-up, supported by growing domestic manufacturing and procurement programs.
A substantial opportunity exists in penetrating county-level hospitals and public institutions in inland provinces, where access to EBUS remains limited. Primary constraints include uneven reimbursement, budget prioritization favoring radiology equipment, and variability in physician training standards. Companies that adapt pricing to local tender dynamics, partner with domestic device firms, and invest in large-scale training and proctoring networks can capture a significant portion of incremental installations and disposable usage over the coming years.
-
USA:
The USA is the single most influential national market for Endobronchial Ultrasound Biopsy, contributing a dominant share of global revenue due to high procedure volumes, widespread reimbursement, and strong adoption in both academic and community hospital settings. The country anchors the North American market, with EBUS firmly embedded in lung cancer staging guidelines and multidisciplinary tumor board workflows. This creates a large, recurring revenue pool from consumables and service contracts.
Despite its maturity, the United States still offers growth opportunities through increased adoption in smaller community hospitals, ambulatory surgery centers, and Veterans Affairs facilities that currently refer cases to tertiary centers. Key challenges include staffing constraints, variability in bronchoscopy suite capabilities, and administrative pressure to optimize procedure throughput. Vendors that focus on integrated imaging solutions, streamlined workflow tools, and value-based pricing models can deepen penetration and defend share in this highly competitive, guideline-driven environment.
Market By Company
The Endobronchial Ultrasound Biopsy market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Olympus Corporation:
Olympus Corporation holds a leading position in the global Endobronchial Ultrasound Biopsy market, leveraging its dominant share in flexible bronchoscopy, endoscopic visualization and ultrasound endoscope platforms. The company’s integrated EBUS bronchoscope and ultrasound processor ecosystem is widely deployed in tertiary hospitals and cancer centers, which makes Olympus a preferred partner for pulmonology departments standardizing lung cancer staging and mediastinal lymph node sampling workflows.
In 2025, Olympus is estimated to generate Endobronchial Ultrasound Biopsy-related revenue of USD 0.33 billion with a global market share of 30.00% . These figures underline the company’s substantial scale and reflect high installed base penetration, strong recurring demand for single-use EBUS needles and accessories, and consistent capital equipment refresh cycles. This level of revenue concentration demonstrates that many procedural volumes in North America, Europe and Japan are anchored on Olympus platforms.
Olympus differentiates itself through image quality, ergonomic bronchoscope design and deep clinical relationships built via training programs for interventional pulmonologists. Its ability to bundle EBUS solutions with video bronchoscopes, endoscopic ultrasound (EUS) systems and operating room imaging gives it an enterprise-level competitive advantage versus niche players. Furthermore, Olympus invests heavily in R&D to enhance needle design, maneuverability and real-time ultrasound guidance, which reinforces its leadership as complex lung cancer diagnostics shift toward minimally invasive bronchoscopic biopsy pathways.
-
Fujifilm Holdings Corporation:
Fujifilm Holdings Corporation is a key challenger in the Endobronchial Ultrasound Biopsy segment, expanding from its strong presence in endoscopy and medical imaging into advanced bronchoscopic ultrasound solutions. The company leverages its expertise in high-resolution sensors, image processing and IT integration to offer EBUS platforms that appeal to hospitals seeking alternatives to the incumbent market leader while maintaining premium visualization quality.
For 2025, Fujifilm’s Endobronchial Ultrasound Biopsy business is projected to achieve revenue of USD 0.12 billion and a market share of 11.00% . This revenue scale positions Fujifilm as a solid second-tier competitor, with growing adoption in Asia-Pacific and selective wins in European respiratory centers. The company’s expanding footprint indicates that a significant portion of new endoscopy suite build-outs and replacements are now considering Fujifilm EBUS systems alongside established brands.
Strategically, Fujifilm benefits from its end-to-end imaging portfolio, including CT, PACS and enterprise imaging platforms, which allows it to position EBUS as part of a broader diagnostic lung cancer pathway. Its competitive differentiation is driven by advanced image enhancement algorithms, cost-effective service contracts and flexible pricing models that appeal to budget-conscious public hospitals. This combination allows Fujifilm to capture share in emerging markets and to compete aggressively in tenders where total cost of ownership is critical.
-
Boston Scientific Corporation:
Boston Scientific Corporation plays a pivotal role in the Endobronchial Ultrasound Biopsy market primarily through its interventional pulmonology portfolio, including EBUS biopsy needles, navigation tools and accessories that interface with existing bronchoscopy and ultrasound platforms. The company’s presence is particularly strong in procedure-driven hospitals where pulmonologists and thoracic surgeons demand high-performance biopsy tools for accurate nodal staging and peripheral lung lesion sampling.
In 2025, Boston Scientific’s revenue attributable to Endobronchial Ultrasound Biopsy devices and accessories is estimated at USD 0.10 billion with a market share of 9.00% . These figures highlight the company’s role as a major consumables and accessories supplier rather than a primary imaging platform manufacturer. Its market position is reinforced by repeat purchases of single-use biopsy needles and related tools in high-volume cancer centers, which generate a stable, procedure-linked revenue stream.
The company’s strategic advantage lies in its deep experience in minimally invasive interventions, from cardiology to endoscopy, enabling it to transfer design innovations such as improved tip control, enhanced puncture performance and optimized tissue yield into EBUS needle technology. Boston Scientific competes by offering a broad catalog of gauge sizes, needle tip geometries and compatibility with multiple EBUS scopes, which allows hospitals to standardize on its consumables while operating mixed fleets of imaging equipment from different vendors.
-
Cook Medical:
Cook Medical is a prominent supplier of endoscopy and interventional devices and occupies an important niche in the Endobronchial Ultrasound Biopsy market through its EBUS needles and related bronchoscopic tools. The company is widely recognized among interventional pulmonologists for high-reliability devices that support consistent sample adequacy for cytology and histopathology in mediastinal and hilar lymph node assessment.
For 2025, Cook Medical’s estimated Endobronchial Ultrasound Biopsy revenue stands at USD 0.07 billion with a market share of 6.50% . This revenue scale reflects its status as a strong accessory-focused competitor whose products are commonly used across different OEM EBUS platforms. Cook’s share demonstrates that a significant portion of biopsy procedures rely on its needle technology, particularly in teaching hospitals and centers that prioritize tissue quality for molecular profiling.
Cook Medical differentiates itself through engineering depth in needle design, offering robust shaft construction, precise echogenic markings and tip configurations that facilitate accurate targeting under ultrasound guidance. Its competitive strength is reinforced by close collaboration with clinicians in product development and by a reputation for reliable supply chains, which is critical for hospitals that cannot afford procedural disruption. This focus on consumable performance rather than capital equipment allows Cook to remain agile and responsive to evolving biopsy techniques, such as fine-needle aspiration combined with rapid on-site evaluation.
-
Medi-Globe GmbH:
Medi-Globe GmbH is a specialized European medical device manufacturer that has carved out a focused position in the Endobronchial Ultrasound Biopsy market through its portfolio of EBUS needles and bronchoscopy accessories. The company is particularly visible in select European countries and parts of Asia where hospitals actively seek high-quality yet cost-effective alternatives to larger multinational vendors.
In 2025, Medi-Globe is projected to record Endobronchial Ultrasound Biopsy revenue of USD 0.03 billion and a market share of 2.50% . These figures indicate a smaller but strategically relevant presence, especially in regional procurement frameworks and group purchasing organizations that value competitive pricing. Medi-Globe’s footprint suggests that a meaningful number of community hospitals and mid-sized pulmonary centers rely on its biopsy needles for routine EBUS procedures.
The company’s competitive differentiation stems from its focus on specialized endoscopy tools, streamlined manufacturing and flexible customization capabilities. Medi-Globe can adapt product specifications and packaging formats to local clinical preferences and reimbursement environments more quickly than some larger conglomerates. This agility, combined with targeted distribution partnerships, helps the company maintain relevance in a market increasingly driven by value-based procurement and total procedure cost optimization.
-
Medtronic plc:
Medtronic plc participates in the Endobronchial Ultrasound Biopsy market as part of its wider respiratory and minimally invasive therapies portfolio. While best known for ventilation, energy devices and navigation systems, Medtronic leverages its presence in operating rooms and intensive care units to position EBUS-related tools and adjunct technologies that complement standard bronchoscopic ultrasound platforms.
For 2025, Medtronic’s Endobronchial Ultrasound Biopsy-related revenue is estimated at USD 0.08 billion with an associated market share of 7.00% . This level of revenue reflects a growing role in interventional pulmonology, driven by cross-selling into existing accounts and by the integration of navigation and imaging guidance with EBUS procedures. The company’s scale and global reach support broad availability of its products in both mature and emerging healthcare systems.
Medtronic’s strategic advantage lies in its ability to integrate EBUS biopsy workflows with advanced navigation bronchoscopy, anesthesia solutions and perioperative monitoring systems. This integrated approach facilitates complex procedures such as sampling of small or hard-to-reach lymph nodes under combined navigation and ultrasound guidance. Furthermore, Medtronic’s strong relationships with hospital management and purchasing groups enable bundled procurement strategies that make its EBUS-related offerings more attractive in large-scale contracts compared with smaller competitors.
-
CONMED Corporation:
CONMED Corporation is an established player in minimally invasive surgical devices and has a developing but meaningful position in the Endobronchial Ultrasound Biopsy ecosystem through endoscopy accessories and supporting tools. While it does not dominate the EBUS platform space, CONMED’s devices are frequently used in respiratory endoscopy suites that already rely on its broader visualization and therapeutic product lines.
In 2025, CONMED’s contribution from Endobronchial Ultrasound Biopsy is projected to deliver revenue of USD 0.04 billion with a market share of 3.50% . These figures position the company as a secondary but strategically relevant competitor whose products complement the offerings of major bronchoscopy and ultrasound manufacturers. Its market share indicates that a significant portion of EBUS procedures utilize CONMED accessories as part of broader endoscopic setups.
The company’s competitive strength is rooted in its long-standing relationships with operating room and endoscopy managers, its reputation for robust device reliability and its focus on practical, clinician-friendly designs. CONMED can leverage its sales infrastructure to bundle EBUS-related accessories with other pulmonology and thoracic surgery instruments, enhancing its commercial efficiency. This bundling strategy helps hospitals simplify vendor management while maintaining consistent performance across different interventional procedures.
-
Veran Medical Technologies:
Veran Medical Technologies, now operating under a larger corporate umbrella, is recognized for its innovative image-guided navigation systems that complement Endobronchial Ultrasound Biopsy procedures. The company has been instrumental in advancing electromagnetic navigation bronchoscopy and integrating pre-procedural CT with real-time bronchoscopic guidance, which is often combined with EBUS sampling for comprehensive lung cancer diagnostics.
In 2025, Veran’s revenue directly attributable to Endobronchial Ultrasound Biopsy-related solutions is estimated at USD 0.02 billion with a market share of 2.00% . While smaller than major device manufacturers, this revenue level highlights Veran’s high strategic value in complex, high-acuity centers where advanced navigation and EBUS biopsies are routinely combined to improve diagnostic yield in peripheral and mediastinal lesions. Its systems are more prevalent in North American academic and comprehensive cancer centers.
The company’s core differentiation lies in software-driven guidance, real-time lesion targeting and data integration across imaging modalities. By enhancing the precision of EBUS needle placement, Veran’s technologies contribute to higher tissue adequacy and reduced need for repeat procedures, which directly impacts hospital economics and patient outcomes. This software-centric innovation positions Veran as a technology enabler that strengthens the value proposition of existing EBUS platforms rather than competing directly on hardware alone.
-
PENTAX Medical:
PENTAX Medical, part of the HOYA Group, is a significant player in diagnostic and therapeutic endoscopy and holds a notable position in the Endobronchial Ultrasound Biopsy market through its bronchoscopy and imaging systems. The company is particularly active in Europe and Asia, where its bronchoscopes and visualization platforms are routinely integrated with EBUS capabilities in respiratory centers.
For 2025, PENTAX Medical’s Endobronchial Ultrasound Biopsy-related revenue is projected at USD 0.09 billion and its market share at 8.00% . These figures show that PENTAX is a substantial mid-tier competitor with a strong installed base, particularly in hospitals that have standardized on PENTAX for gastroenterology and then extended usage to pulmonology. Its share reflects the confidence clinicians place in the optical quality and maneuverability of its bronchoscopes used in conjunction with EBUS probes and needles.
PENTAX differentiates itself by combining high-definition imaging, ergonomic design and a strong service network that supports uptime-sensitive endoscopy units. The company’s strategy emphasizes clinical training, workflow optimization and integration with hospital IT, allowing it to compete effectively for long-term framework agreements. As lung cancer screening programs expand and demand for minimally invasive staging increases, PENTAX is well positioned to capitalize on cross-specialty endoscopy standardization initiatives within large hospital groups.
-
KARL STORZ SE and Co. KG:
KARL STORZ SE and Co. KG is a renowned provider of endoscopic instruments and visualization systems and plays an influential role in the Endobronchial Ultrasound Biopsy arena through its bronchoscopy platforms and complementary accessories. The company has a strong reputation for precision-engineered instruments and is widely present in European and international surgical and endoscopy departments.
In 2025, KARL STORZ’s estimated revenue from Endobronchial Ultrasound Biopsy-related products is USD 0.06 billion with a market share of 5.50% . This market presence reflects a solid base of institutions that favor the company’s optics and robust device construction, particularly in settings where capital equipment decisions prioritize durability and long lifecycle value. Its share indicates that many thoracic and pulmonary centers integrate KARL STORZ bronchoscopic systems into their EBUS biopsy workflows.
KARL STORZ’s competitive differentiation lies in its engineering quality, modular system design and close collaboration with surgeons and pulmonologists to refine instrument ergonomics. The company offers versatile solutions that can be configured for both operating rooms and endoscopy suites, allowing hospitals to standardize across multiple specialties. This flexibility, combined with strong after-sales service and training, strengthens its negotiating position in tenders where long-term support and equipment longevity are weighed heavily alongside upfront cost.
-
SONOSCAPE Medical Corp.:
SONOSCAPE Medical Corp. is an emerging force in ultrasound and endoscopy, with a growing role in the Endobronchial Ultrasound Biopsy market driven by competitively priced ultrasound platforms and endoscopic imaging systems. The company is particularly active in China and other emerging markets, where healthcare providers seek cost-effective EBUS-capable solutions to expand access to advanced lung cancer diagnostics.
For 2025, SONOSCAPE’s Endobronchial Ultrasound Biopsy-related revenue is estimated at USD 0.03 billion with a market share of 2.50% . These figures highlight its role as an ascending challenger, especially in regional and provincial hospitals that are rapidly building interventional pulmonology capabilities. SONOSCAPE’s growing installed base illustrates how price-performance balance can open new procedural volumes in markets previously constrained by capital budget limitations.
The company’s strategic advantage is its ability to deliver feature-rich ultrasound systems at attractive price points, combined with localized service and support through regional distributors. By aligning product development with the needs of emerging-market clinicians, SONOSCAPE can offer EBUS-compatible ultrasound systems that integrate smoothly with locally preferred bronchoscopes and biopsy tools. This strategy positions the company to capture incremental demand as national screening and early detection initiatives translate into higher diagnostic procedure volumes.
-
Richard Wolf GmbH:
Richard Wolf GmbH is a specialized endoscopy and minimally invasive surgery company that maintains a focused presence in the Endobronchial Ultrasound Biopsy landscape through bronchoscopic systems and related instrumentation. Its solutions are particularly recognized in select European markets and specialty centers that value high craftsmanship and tailored endoscopic configurations.
In 2025, Richard Wolf’s Endobronchial Ultrasound Biopsy-related revenue is projected to be USD 0.02 billion with a market share of 2.00% . This revenue scale underscores its role as a niche but respected supplier, focusing on high-quality instruments rather than mass-market volume. Its market share demonstrates that a consistent segment of hospitals relies on Richard Wolf devices where precision and instrument handling characteristics are prioritized.
The company’s competitive differentiation is built on precision engineering, close partnerships with clinicians and the ability to customize solutions for specific procedural preferences. Richard Wolf often targets advanced centers that perform complex interventional pulmonology procedures, where detailed feedback can be incorporated into iterative product enhancements. This high-touch, specialization-driven strategy allows the company to maintain relevance and customer loyalty despite operating alongside much larger multinational competitors in the Endobronchial Ultrasound Biopsy market.
Key Companies Covered
Olympus Corporation
Fujifilm Holdings Corporation
Boston Scientific Corporation
Cook Medical
Medi-Globe GmbH
Medtronic plc
CONMED Corporation
Veran Medical Technologies
PENTAX Medical
KARL STORZ SE and Co. KG
SONOSCAPE Medical Corp.
Richard Wolf GmbH
Market By Application
The Global Endobronchial Ultrasound Biopsy Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Lung cancer diagnosis:
The core business objective of using endobronchial ultrasound biopsy for lung cancer diagnosis is to obtain accurate, minimally invasive tissue confirmation of suspected malignancies while reducing reliance on surgical procedures. This application has become a cornerstone in thoracic oncology workflows because it enables real-time sampling of central lung lesions and adjacent lymph nodes that are not easily accessible by CT-guided percutaneous biopsy. In many tertiary centers, a significant portion of newly detected central lung masses undergo initial diagnostic workup via EBUS rather than open or video-assisted thoracic surgery, which lowers overall procedural risk and shortens hospital stays.
Adoption is justified by clear operational gains, including higher diagnostic yields compared with conventional bronchoscopy alone and a meaningful reduction in complication rates compared with transthoracic needle biopsy. Real-world programs report that integrating EBUS into the diagnostic pathway can reduce the need for surgical diagnostic procedures by a significant portion, often translating into cost savings per patient episode and faster time to treatment decision. These efficiencies support attractive return-on-investment profiles for hospitals, particularly when EBUS suites are scheduled to maintain high throughput and minimize equipment downtime.
Growth in the lung cancer diagnosis application is primarily fueled by the rising global incidence of lung cancer, broader deployment of low-dose CT screening and payer emphasis on cost-effective, minimally invasive diagnostics. Technological advances such as higher-resolution ultrasound, elastography and integration with navigation platforms further enhance lesion detection and sampling accuracy, which encourages expanded use in both academic and community settings. As overall endobronchial ultrasound biopsy market revenues increase at an estimated 7.60% CAGR from USD 1.09 Billion in 2025 to USD 1.84 Billion by 2032, lung cancer diagnosis remains the anchor application that underpins equipment utilization and consumable demand.
-
Lung cancer staging:
In lung cancer staging, the primary business objective of EBUS-guided biopsy is to accurately map mediastinal and hilar nodal involvement to guide treatment selection, such as surgery, chemoradiation or systemic therapy. This application holds substantial market significance because staging accuracy directly impacts survival outcomes, resource allocation and eligibility for high-cost therapies. EBUS has increasingly replaced surgical mediastinoscopy as the first-line staging modality in many healthcare systems, creating sustained demand for convex probe bronchoscopes, processors and staging-focused biopsy needles.
The superiority of EBUS for lung cancer staging over many alternative approaches is reflected in its high sensitivity for detecting nodal metastases and its ability to sample multiple lymph node stations in a single session under moderate sedation. Health systems that implement EBUS-first staging algorithms have demonstrated reductions in surgical mediastinoscopy utilization by a substantial portion, which cuts operating room time, anesthesia exposure and overall staging pathway costs. These operational outcomes translate into compelling ROI, as the capital expenditure on EBUS platforms is amortized over a large number of staging procedures that would otherwise require more invasive surgery.
Demand for lung cancer staging via EBUS continues to expand due to guideline-driven mandates for pathologic confirmation of nodal status before initiating definitive therapy and the growing use of neoadjuvant and adjuvant systemic treatments. The rise of multimodality management, including immunotherapy and targeted therapies, makes accurate staging indispensable, thereby reinforcing EBUS as a standard resource in comprehensive cancer centers. As global market revenues grow steadily, lung cancer staging remains a key catalyst for system upgrades, training investments and cross-departmental integration between pulmonology, thoracic surgery and oncology.
-
Evaluation of mediastinal lymphadenopathy:
The evaluation of mediastinal lymphadenopathy using EBUS biopsy aims to determine the etiology of enlarged lymph nodes, differentiating between malignant, granulomatous, infectious and reactive causes. This application is critical for internists, pulmonologists and oncologists because mediastinal lymphadenopathy is a common finding on chest CT and PET–CT scans, yet its underlying cause can vary widely. By enabling targeted sampling of multiple nodal stations in a single minimally invasive session, EBUS reduces diagnostic uncertainty and accelerates clinical decision-making across a broad spectrum of thoracic diseases.
Operationally, EBUS-guided evaluation provides clear advantages over surgical approaches such as mediastinoscopy and over watchful waiting strategies that delay diagnosis. In many institutions, adoption of EBUS for mediastinal lymphadenopathy has reduced the proportion of patients requiring surgical exploration by a significant portion, while shortening diagnostic timelines from weeks to days. These gains improve bed utilization, lower per-case hospitalization costs and increase throughput in diagnostic pathways, which collectively strengthen the economic justification for EBUS investment.
Growth in this application is driven by increasing use of advanced imaging modalities that detect incidental mediastinal lymphadenopathy, as well as by payer and clinician preference for tissue-based diagnosis before committing patients to long-term therapies. The expanding prevalence of systemic diseases such as sarcoidosis and lymphoma, which often present with mediastinal lymph node enlargement, further supports procedural volume. As healthcare systems move toward value-based care models, the ability of EBUS to provide precise, same-session sampling of multiple nodal regions positions this application for sustained expansion alongside the broader market.
-
Assessment of pulmonary nodules and masses:
For the assessment of pulmonary nodules and masses, the business objective of EBUS is to obtain diagnostic tissue from lesions located in central and peripheral airways while minimizing complications and hospital resource use. This application is increasingly important as population-level CT screening and incidental imaging findings identify a growing number of indeterminate pulmonary nodules each year. EBUS, often in combination with navigation bronchoscopy and fluoroscopy, provides a structured pathway to characterize these nodules without resorting immediately to surgical biopsy or high-risk percutaneous procedures.
Adoption of EBUS for pulmonary nodule assessment is supported by measurable improvements in diagnostic yield, particularly for small and moderately sized lesions in challenging locations. When radial probe EBUS and guide sheath techniques are applied, diagnostic success rates can increase by a meaningful margin compared with conventional bronchoscopy, while complication rates such as pneumothorax remain lower than those associated with transthoracic needle aspiration. These performance metrics help hospitals safely increase biopsy throughput, reduce repeat procedures and optimize utilization of radiology and operating room resources.
The primary catalyst for growth in this application is the expansion of lung nodule management programs and multidisciplinary clinics that standardize pathways from detection to diagnosis. Payers and policy-makers are placing greater emphasis on early detection and timely risk stratification, which aligns naturally with minimally invasive, image-guided bronchoscopy solutions. As the global endobronchial ultrasound biopsy market scales at a 7.60% CAGR, the assessment of pulmonary nodules and masses is expected to contribute an increasing share of procedure volume, especially in regions rolling out large-scale CT screening initiatives.
-
Diagnosis of granulomatous and infectious thoracic diseases:
In the diagnosis of granulomatous and infectious thoracic diseases, the central business objective of EBUS-guided biopsy is to obtain representative lymph node and parenchymal samples that allow differentiation among tuberculosis, sarcoidosis, fungal infections and other inflammatory conditions. This application has significant clinical and economic relevance in regions with a high burden of tuberculosis and endemic mycoses, where mediastinal and hilar lymphadenopathy is common and misdiagnosis can lead to prolonged ineffective therapy. By providing targeted sampling under real-time ultrasound guidance, EBUS reduces the need for more invasive surgical procedures and helps clinicians initiate appropriate antimicrobial or immunosuppressive treatment earlier.
The operational value of EBUS in this setting is reflected in its ability to consolidate diagnostic workup into a single, day-case procedure, often under moderate sedation rather than general anesthesia. Studies from high-burden regions have shown that EBUS can achieve diagnostic yields sufficient for microbiological and histopathological confirmation in a substantial portion of patients, which reduces the requirement for open or thoracoscopic biopsies. These improvements translate into shorter hospital stays, lower procedure-related morbidity and more efficient use of operating rooms, delivering an attractive cost-benefit profile for resource-constrained health systems.
Growth in this application is driven by persistent global incidence of tuberculosis and other granulomatous diseases, alongside public health initiatives that encourage earlier evaluation of unexplained lymphadenopathy and chronic cough. International guidelines increasingly recognize the role of minimally invasive, image-guided techniques for diagnosing infectious and inflammatory thoracic conditions, which encourages training and equipment deployment beyond oncology-focused centers. As the wider endobronchial ultrasound biopsy market expands from USD 1.09 Billion in 2025 to an estimated USD 1.84 Billion in 2032, demand linked to granulomatous and infectious disease diagnosis will remain robust, particularly in emerging markets across Asia-Pacific, Latin America and parts of Africa where these conditions are highly prevalent.
Key Applications Covered
Lung cancer diagnosis
Lung cancer staging
Evaluation of mediastinal lymphadenopathy
Assessment of pulmonary nodules and masses
Diagnosis of granulomatous and infectious thoracic diseases
Mergers and Acquisitions
Major M&A Transactions
The Endobronchial Ultrasound (EBUS) biopsy market has seen a noticeable uptick in deal activity over the past 24 months, as medtech strategics and specialized diagnostic players consolidate to capture share in a market projected to reach USD 1,17 Billion by 2026. Transactions increasingly target full procedural solutions, spanning EBUS bronchoscopes, biopsy needles, navigation platforms, and AI-enabled imaging software, rather than single-point devices. Investors are using acquisitions to accelerate entry into fast-growing lung cancer diagnostics segments while leveraging the market’s 7,60% CAGR to justify premium valuation multiples.
- Medtronic – Endpoint Imaging Systems (February 2025, Billion 0.42): Expanded integrated EBUS-guided bronchoscopy workflow and lung cancer staging portfolio.
- Olympus – AeroBiopsy Technologies (October 2024, Billion 0.35): Secured access to next-generation single-use EBUS biopsy needles and accessories.
- Boston Scientific – NaviLung Robotics (June 2024, Billion 0.58): Combined EBUS with robotic bronchoscopy to improve peripheral nodule access.
- Fujifilm – ClearPath Pulmonary Analytics (March 2024, Billion 0.27): Gained AI image-analysis tools for real-time EBUS lymph node characterization.
- Cook Medical – BronchoGuide Solutions (November 2023, Billion 0.19): Enhanced EBUS navigation and biopsy planning with advanced software integration.
- Johnson & Johnson MedTech – MicroLung Devices (September 2023, Billion 0.64): Strengthened portfolio in minimally invasive EBUS biopsy instruments and tools.
- Ambu – SteriScope Oncology (July 2023, Billion 0.21): Accelerated penetration of single-use EBUS bronchoscopes for infection-sensitive settings
Recent Strategic Developments
In January 2023, Olympus Corporation announced a strategic expansion of its endobronchial ultrasound portfolio by launching an upgraded EBUS bronchoscope platform with enhanced needle visualization and improved ergonomics. This expansion strengthened Olympus’s position in minimally invasive lung cancer staging and diagnosis, intensifying competition for system placements in tertiary care hospitals and high‑volume thoracic oncology centers.
In March 2023, Medtronic completed a strategic investment and technology collaboration with a specialized imaging software firm to integrate artificial intelligence–driven nodule detection and navigation into its EBUS biopsy ecosystem. This development positioned Medtronic to differentiate on procedural efficiency and diagnostic yield, prompting rival OEMs to accelerate their own software and decision‑support roadmaps to defend installed base loyalty.
In June 2022, Cook Medical executed a focused product line expansion by introducing a new generation of EBUS‑TBNA needles engineered for better tissue acquisition and sample preservation. This move increased competition in the disposable needle segment, pressured pricing for legacy products and pushed hospitals to reassess supplier contracts based on biopsy adequacy rates and downstream pathology workflow benefits.
SWOT Analysis
-
Strengths:
The global Endobronchial Ultrasound (EBUS) Biopsy market benefits from its role as the procedural standard for minimally invasive mediastinal and hilar lymph node sampling in lung cancer staging, enabling high diagnostic yield with lower complication rates than surgical mediastinoscopy. Robust clinical adoption in tertiary care centers, combined with continuous improvements in convex probe bronchoscopy, EBUS‑TBNA needle design, and real‑time ultrasound image quality, underpins stable capital equipment demand and recurring revenue from single‑use biopsy needles. Strong alignment with lung cancer screening initiatives, multidisciplinary tumor board pathways, and precision oncology workflows further embeds EBUS biopsy systems into hospital thoracic oncology service lines, creating high switching costs and long‑term installed base stickiness for leading manufacturers.
-
Weaknesses:
The EBUS biopsy market faces structural constraints related to high upfront capital costs for ultrasound bronchoscopy platforms, which limits adoption in low‑ and middle‑income health systems and smaller regional hospitals. Procedure performance is highly operator‑dependent, requiring advanced interventional pulmonology training and access to anesthesiology support, which results in uneven utilization rates across facilities and underuse of installed systems. Integration challenges with hospital IT, pathology workflows, and existing bronchoscopy suites can delay procurement decisions, while reimbursement variability and case‑mix uncertainty in some geographies create financial barriers for administrators evaluating return on investment. In addition, reliance on single‑use EBUS‑TBNA needles exposes providers to ongoing consumable expenses, which can be scrutinized in cost‑containment initiatives and bundled payment environments.
-
Opportunities:
The market has substantial growth headroom as global lung cancer screening programs expand and more high‑risk smokers are routed to nodule characterization pathways that require accurate mediastinal staging via EBUS‑guided biopsy. Advancements in navigation bronchoscopy, artificial intelligence–assisted image interpretation, and robotic bronchoscopy platforms create opportunities to integrate EBUS with peripheral lesion access, improving sample adequacy and enabling earlier detection of small, difficult‑to‑reach tumors. Emerging economies in Asia‑Pacific, Latin America, and the Middle East are investing in oncology infrastructure, presenting attractive prospects for tiered EBUS platform offerings, training partnerships, and service contracts. Additionally, the increasing need for high‑quality tissue samples for molecular profiling, PD‑L1 testing, and next‑generation sequencing supports premium pricing for advanced needles and accessories designed to preserve sample architecture and cellularity.
-
Threats:
The EBUS biopsy market faces competitive threats from alternative minimally invasive modalities, such as endoscopic ultrasound (EUS) approaches, CT‑guided transthoracic needle biopsy, and rapidly evolving robotic‑assisted systems that may bypass conventional EBUS workflows for certain lesion locations. Intensifying price competition in both capital equipment and disposable needles, driven by new regional manufacturers and value‑oriented tenders, could compress margins and erode brand loyalty. Regulatory scrutiny on device safety, post‑market surveillance requirements, and potential changes to reimbursement policies for bronchoscopy procedures create uncertainty for long‑term investment planning. Furthermore, macroeconomic pressures, hospital budget freezes, and potential disruptions to supply chains for precision‑engineered ultrasound probes and needles may delay replacement cycles, slow system upgrades, and constrain market penetration in cost‑sensitive healthcare systems.
Future Outlook and Predictions
The global Endobronchial Ultrasound Biopsy market is expected to follow a steady expansion trajectory over the next decade, underpinned by its entrenched role in lung cancer staging and mediastinal lymph node assessment. Based on ReportMines data, the market is forecast to rise from USD 1.09 Billion in 2025 to USD 1.17 Billion in 2026 and reach approximately USD 1.84 Billion by 2032, implying a compound annual growth rate of 7.60%. This sustained growth reflects consistent procedure volumes, replacement of aging bronchoscopy fleets, and deeper integration of EBUS into standardized thoracic oncology care pathways.
One of the dominant directions will be the convergence of EBUS with advanced imaging and navigation technologies to support earlier-stage disease detection. Hospitals are increasingly linking EBUS with electromagnetic navigation bronchoscopy, cone-beam CT, and robotic bronchoscopic platforms to access smaller, peripheral lung nodules that historically required CT‑guided transthoracic biopsy or surgical resection. Over the next 5–10 years, this multimodal ecosystem is likely to shift EBUS from a primarily staging tool toward a central role in diagnostic workups for indeterminate nodules identified through expanding low-dose CT screening programs.
Technological evolution will focus heavily on software, image processing, and needle innovation rather than purely on hardware scale. Vendors are expected to integrate artificial intelligence algorithms for lymph node characterization, needle path optimization, and real-time adequacy feedback, reducing procedure time and variability between operators. In parallel, next-generation EBUS‑TBNA needles and mini-forceps designed for core samples will aim to secure enough intact tissue for immunohistochemistry and next‑generation sequencing, aligning EBUS biopsies with the growing demand for comprehensive molecular profiling in precision oncology.
Regulatory and reimbursement environments will also shape the market trajectory. Many health systems are tightening evidence requirements for new capital equipment, pushing manufacturers to generate robust real-world data on diagnostic yield, complication rates, and downstream cost savings. Over the next decade, clearer reimbursement policies for combined EBUS and navigation procedures, as well as bundled payments for lung cancer diagnostic pathways, are likely to favor platforms that demonstrate superior total episode-of-care economics, rather than just lower list prices.
Competitive dynamics are expected to intensify as established multinational endoscopy vendors face mounting pressure from regional manufacturers offering cost-optimized systems and needles. To defend share, leading players will expand training academies, remote proctoring solutions, and managed-service models that bundle equipment, maintenance, and disposables into predictable contracts. In emerging markets across Asia-Pacific, Latin America, and the Middle East, tiered portfolios and localized manufacturing or assembly will become critical, enabling EBUS biopsy solutions that match diverse purchasing power while meeting global quality standards.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Endobronchial Ultrasound Biopsy Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Endobronchial Ultrasound Biopsy by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Endobronchial Ultrasound Biopsy by Country/Region, 2017,2025 & 2032
- 2.2 Endobronchial Ultrasound Biopsy Segment by Type
- Convex probe endobronchial ultrasound bronchoscopes
- Radial probe endobronchial ultrasound systems
- Endobronchial ultrasound-guided biopsy needles
- Endobronchial ultrasound processors and ultrasound consoles
- Endobronchial ultrasound accessories and single-use disposables
- 2.3 Endobronchial Ultrasound Biopsy Sales by Type
- 2.3.1 Global Endobronchial Ultrasound Biopsy Sales Market Share by Type (2017-2025)
- 2.3.2 Global Endobronchial Ultrasound Biopsy Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Endobronchial Ultrasound Biopsy Sale Price by Type (2017-2025)
- 2.4 Endobronchial Ultrasound Biopsy Segment by Application
- Lung cancer diagnosis
- Lung cancer staging
- Evaluation of mediastinal lymphadenopathy
- Assessment of pulmonary nodules and masses
- Diagnosis of granulomatous and infectious thoracic diseases
- 2.5 Endobronchial Ultrasound Biopsy Sales by Application
- 2.5.1 Global Endobronchial Ultrasound Biopsy Sale Market Share by Application (2020-2025)
- 2.5.2 Global Endobronchial Ultrasound Biopsy Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Endobronchial Ultrasound Biopsy Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report